Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 8/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20549568 | 0.90 | TLR2 (0.43) | TLR2HIF1AALDH1A1KDM4ELMNA | |
| SCHEMBL20549436 | 0.88 | TLR2 (0.38) | TLR2HIF1AALDH1A1KDM4ELMNA | |
| SCHEMBL20549184 | 0.81 | — | — | |
| SCHEMBL20549518 | 0.78 | ALDH1A1 (0.33) | ALDH1A1KDM4ELMNAKMT2A | |
| SCHEMBL20549259 | 0.73 | LMNA (0.32) | TLR2HIF1AALDH1A1KDM4ELMNA | |
| SCHEMBL20549545 | 0.70 | KDM4E (0.39) | TLR2HIF1AALDH1A1KDM4ELMNA | |
| SCHEMBL20549502 | 0.70 | HIF1A (0.36) | TLR2HIF1AALDH1A1KDM4ELMNA | |
| SCHEMBL20549817 | 0.68 | ALDH1A1 (0.34) | TLR2HIF1AALDH1A1KDM4ELMNA | |
| SCHEMBL19086540 | 0.66 | HIF1A (0.45) | HIF1AALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL19478316 | 0.61 | CA1 (0.45) | KDM4ELMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180318311-A1 | TRICYCLIC 2-QUINOLINONES AS ANTIBACTERIALS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2018-11-08 | — | — | US | disclosed |
| WO-2018203302-A1 | TRICYCLIC 2-QUINOLINONES AS ANTIBACTERIALS | NOVARTIS AG (CH) | 2018-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180318311-A1 | TRICYCLIC 2-QUINOLINONES AS ANTIBACTERIALS | TOP1, TOP2A, TOP2B | TLR2 967/4885HIF1A 2739/4885ALDH1A1 1696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.